Skip to main content

Andrew Mignatti

Perthera announced that Andrew Mignatti has joined the firm as CEO. Mignatti joins Perthera from RedPath, where he served as senior VP of operations. Mignatti also previously worked with Esoterix and Laboratory Corporation of America and has more than 15 years of experience in the pathology, laboratory, and diagnostic fields. Mignatti is a graduate of Saint Edward University in Austin, Texas.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.